Compare Lithium Americas Corp (LAC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs GeneDx Holdings Corp — how do they compare? Lithium Americas Corp trades at $2.35 (market cap $850.38M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.4× Lithium Americas Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and GeneDx Holdings Corp for 19 Days on average.
| LAC | WGS | |
|---|---|---|
Market Cap | $850.38M | $2.02B |
Volume | 8,804,637 | 734,640 |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $167.51 |
52-Week Low | $2.36 | $34.51 |
Typical Hold Time | 27 Days | 19 Days |
Enterprise Value | $1.19B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.36, down 2.07% with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -9.56% and ROA at -3.99%, though it has beaten EPS estimates in recent quarters. Analyst consensus is mixed with 47% buy ratings and a $4.00 price target, representing 69% upside potential. Recent news highlights construction progress at Thacker Pass and a $175 million financing round to strengthen the balance sheet.
LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The stock trades below book value (P/B 0.6) but faces significant execution risks and negative cash flow from operations. Upside depends on successful lithium production ramp-up and favorable lithium pricing, while downside risks include project delays and commodity price volatility.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
